Long‐term outcomes after prophylactic ICD and CRT‐D implantation in nonischemic patients: Analysis from a nationwide database of daily remote‐monitoring transmissions

Introduction: Clinical trials did not provide conclusive evidence concerning the benefit of prophylactic implantable cardioverter‐defibrillators (ICDs) in patients with severe nonischemic cardiomyopathy (NICM). We aimed to compare incidence of appropriate sustained ventricular arrhythmia (SVA) and device therapy in ischemic cardiomyopathy (ICM) vs NICM ICD and/or cardiac resynchronization therapy (CRT‐D) patients.

[1]  P. Della Bella,et al.  Organizational model and reactions to alerts in remote monitoring of cardiac implantable electronic devices: A survey from the Home Monitoring Expert Alliance project , 2018, Clinical cardiology.

[2]  G. Hindricks,et al.  Remote monitoring and clinical outcomes: details on information flow and workflow in the IN-TIME study , 2018, European heart journal. Quality of care & clinical outcomes.

[3]  Lurdes Y. T. Inoue,et al.  Primary Prevention Implantable Cardioverter Defibrillators in Patients With Nonischemic Cardiomyopathy: Diminishing Returns With Advancing Age? , 2017, Circulation.

[4]  Michael J Ackerman,et al.  2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. , 2017, Journal of the American College of Cardiology.

[5]  William J. Bryant,et al.  2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Executive summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. , 2017, Heart rhythm.

[6]  Y. Reddy,et al.  Efficacy of Implantable Cardioverter-Defibrillator Therapy in Patients With Nonischemic Cardiomyopathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. , 2017, JACC. Clinical electrophysiology.

[7]  S. Solomon,et al.  Declining Risk of Sudden Death in Heart Failure , 2017, The New England journal of medicine.

[8]  Z. Whinnett,et al.  Implantable cardioverter defibrillators for primary prevention of death in left ventricular dysfunction with and without ischaemic heart disease: a meta-analysis of 8567 patients in the 11 trials , 2017, European heart journal.

[9]  L. Fauchier,et al.  Implantable cardioverter-defibrillator therapy among patients with non-ischaemic vs. ischaemic cardiomyopathy for primary prevention of sudden cardiac death , 2017, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[10]  Hans Eiskjær,et al.  Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. , 2016, The New England journal of medicine.

[11]  P. Kirchhof,et al.  2015 ESC Guidelines for the Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. , 2016, Revista espanola de cardiologia.

[12]  C. O'connor,et al.  Comparison of Medical Therapy Dosing in Outpatients Cared for in Cardiology Practices With Heart Failure and Reduced Ejection Fraction With and Without Device Therapy: Report From IMPROVE HF , 2010, Circulation. Heart failure.

[13]  Douglas L Packer,et al.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. , 2005, The New England journal of medicine.

[14]  Akshay S. Desai,et al.  Implantable Defibrillators for the Prevention of Mortality in Patients With Nonischemic Cardiomyopathy: A Meta-analysis of Randomized Controlled Trials , 2004 .

[15]  Hugh Calkins,et al.  Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. , 2004, The New England journal of medicine.

[16]  A. Kadish,et al.  DEFibrillators In Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE). , 2003, Cardiac electrophysiology review.

[17]  F. Morady,et al.  Amiodarone versus implantable cardioverter-defibrillator:randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia--AMIOVIRT. , 2003, Journal of the American College of Cardiology.

[18]  K. Kuck,et al.  Primary Prevention of Sudden Cardiac Death in Idiopathic Dilated Cardiomyopathy: The Cardiomyopathy Trial (CAT) , 2002, Circulation.

[19]  J. Oss,et al.  PROPHYLACTIC IMPLANTATION OF A DEFIBRILLATOR IN PATIENTS WITH MYOCARDIAL INFARCTION AND REDUCED EJECTION FRACTION , 2002 .

[20]  Á. Arenal,et al.  Survival and arrhythmic risk among ischemic and non-ischemic heart failure patients with prophylactic implantable cardioverter defibrillator only therapy: A propensity score-matched analysis. , 2019, International journal of cardiology.

[21]  M. Cheitlin.  Are Implantable Cardioverter Defibrillator Shocks a Surrogate for Sudden Cardiac Death in Patients With Nonischemic Cardiomyopathy , 2007 .